Aquestive Therapeutics (NASDAQ:AQST) Earns “Buy” Rating from HC Wainwright

Aquestive Therapeutics (NASDAQ:AQST)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Monday,Benzinga reports. They currently have a $10.00 price target on the stock. HC Wainwright’s target price would indicate a potential upside of 114.59% from the company’s current price.

A number of other research firms have also commented on AQST. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Friday, July 17th. Wall Street Zen downgraded Aquestive Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, August 15th. Two analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $8.80.

Aquestive Therapeutics Stock Performance

NASDAQ:AQST opened at $4.66 on Monday. The firm has a market capitalization of $584.89 million, a PE ratio of -7.17 and a beta of 1.49. Aquestive Therapeutics has a 1 year low of $2.93 and a 1 year high of $7.55. The firm’s fifty day simple moving average is $4.18 and its 200 day simple moving average is $4.12.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.08). The business had revenue of $13.82 million for the quarter, compared to analysts’ expectations of $11.42 million. As a group, analysts anticipate that Aquestive Therapeutics will post -0.5 EPS for the current fiscal year.

Insider Transactions at Aquestive Therapeutics

In related news, Director Julie Krop sold 25,000 shares of the company’s stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total transaction of $125,500.00. Following the completion of the transaction, the director directly owned 25,000 shares in the company, valued at $125,500. This represents a 50.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 6.81% of the company’s stock.

Institutional Trading of Aquestive Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. NewEdge Advisors LLC bought a new position in shares of Aquestive Therapeutics during the 3rd quarter worth about $28,000. BNP Paribas Financial Markets lifted its stake in shares of Aquestive Therapeutics by 78.3% in the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after buying an additional 4,134 shares during the period. Modern Wealth Management LLC bought a new stake in shares of Aquestive Therapeutics in the second quarter valued at about $33,000. Elevation Point Wealth Partners LLC acquired a new stake in Aquestive Therapeutics during the first quarter worth about $42,000. Finally, ADAR1 Capital Management LLC grew its position in Aquestive Therapeutics by 103.9% during the first quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock worth $42,000 after buying an additional 264,000 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors and hedge funds.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.